Literature DB >> 22268645

Direct analysis of 5-methylcytosine and 5-methyl-2'-deoxycytidine in human urine by isotope dilution LC-MS/MS: correlations with N-methylated purines and oxidized DNA lesions.

Chiung-Wen Hu1, Hung-Hsin Liu, Yi-Jie Li, Mu-Rong Chao.   

Abstract

Recent evidence suggests that active DNA demethylation involves base excision repair (BER) and nucleotide excision repair (NER) pathways. We hypothesized that the resulting excision products could be further excreted and present in urine. A highly specific and sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was first developed for simultaneously measuring urinary 5-methylcytosine (5-meC) and 5-methyl-2'-deoxycytidine (5-medC). With the use of isotope internal standards and online solid-phase extraction (SPE), the detection limits of 5-meC and 5-medC were estimated to be 1.2 and 0.3 pg, respectively. This method was applied to measure urinary samples of 376 healthy males. Urinary samples were also measured for methylated and oxidized DNA lesions, namely, N7-methylguanine (N7-meG), N3-methyladenine (N3-meA), 8-oxo-7,8-dihydroguanine (8-oxoGua), and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), using reported online SPE LC-MS/MS methods. Results showed that mean urinary levels of 5-meC and 5-medC were 28.4 ± 14.3 and 7.04 ± 7.2 ng/mg creatinine, respectively, supporting the possible presence of DNA demethylation through BER and NER mechanisms. Urinary levels of 5-meC were significantly positively correlated with N7-meG, N3-meA, and 8-oxodG. Good correlations between 5-meC and methylated and oxidized DNA lesions may have implied the underlying linkage between genetic (DNA lesions) and epigenetic (DNA methylation) alterations derived from exogenous exposure and/or from endogenous cellular processes in human and require further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22268645     DOI: 10.1021/tx2004954

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  6 in total

Review 1.  Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.

Authors:  Paul L Wood
Journal:  Neuropsychopharmacology       Date:  2013-07-11       Impact factor: 7.853

Review 2.  Mass spectrometry of structurally modified DNA.

Authors:  Natalia Tretyakova; Peter W Villalta; Srikanth Kotapati
Journal:  Chem Rev       Date:  2013-02-26       Impact factor: 60.622

3.  A novel malic acid-enhanced method for the analysis of 5-methyl-2'-deoxycytidine, 5-hydroxymethyl-2'-deoxycytidine, 5-methylcytidine and 5-hydroxymethylcytidine in human urine using hydrophilic interaction liquid chromatography-tandem mass spectrometry.

Authors:  Cheng Guo; Cong Xie; Qin Chen; Xiaoji Cao; Mengzhe Guo; Shu Zheng; Yinsheng Wang
Journal:  Anal Chim Acta       Date:  2018-07-03       Impact factor: 6.558

4.  Urinary Measurement of Epigenetic DNA Modifications: A Non-Invasive Assessment of the Whole-Body Epigenetic Status in Healthy Subjects and Colorectal Cancer Patients.

Authors:  Rafal Rozalski; Daniel Gackowski; Agnieszka Siomek-Gorecka; Zbigniew Banaszkiewicz; Ryszard Olinski
Journal:  ChemistryOpen       Date:  2016-11-15       Impact factor: 2.911

5.  Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics.

Authors:  M A Fernández-Peralbo; E Gómez-Gómez; M Calderón-Santiago; J Carrasco-Valiente; J Ruiz-García; M J Requena-Tapia; M D Luque de Castro; F Priego-Capote
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

6.  Urine 5MedC, a Marker of DNA Methylation, in the Progression of Chronic Kidney Disease.

Authors:  Akifumi Onishi; Hitoshi Sugiyama; Masashi Kitagawa; Toshio Yamanari; Keiko Tanaka; Ayu Ogawa-Akiyama; Yuzuki Kano; Koki Mise; Katsuyuki Tanabe; Hiroshi Morinaga; Masaru Kinomura; Haruhito A Uchida; Jun Wada
Journal:  Dis Markers       Date:  2019-07-01       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.